Literature DB >> 19207978

Hepatitis D: the comeback?

Mario Rizzetto1.   

Abstract

Hepatitis D virus (HDV) infection has considerably diminished in Europe since the 1970-1980s. The prevalence rates of chronic hepatitis D in HBsAg carriers in Italy have declined from 25% at the beginning of the 1980s to 8% in the 1990s. Similar declines in prevalence have been reported in Spain, Taiwan and Turkey. Better public health standards, HBV vaccination and the effect of measures to control the spread of human immunodeficiency virus have brought about a decline in the numbers of HBsAg carriers and therefore a decline in the HBV-dependent HDV. However, HDV has not declined further in Europe in the last decade, as the pool of fresh infections in migrants from HDV-endemic areas is counterbalancing the shrinking cohort of long-standing domestic infections acquired in the epidemic of the 1970-1980s. Hepatitis D remains an important health problem outside Europe, and new foci of infection continue to be identified in developing countries.

Entities:  

Mesh:

Year:  2009        PMID: 19207978     DOI: 10.1111/j.1478-3231.2008.01937.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  4 in total

1.  Hepatitis D infection in Nigeria.

Authors:  C A Onyekwere; R A Audu; F Duro-Emmanuel; F A Ige
Journal:  Indian J Gastroenterol       Date:  2012-01

2.  Epidemiology of hepatitis D virus (HDV) infection in an urban area of northern Italy.

Authors:  M De Paschale; M T Manco; L Belvisi; C Magnani; T Re; P Viganò; S Biagiotti; F Capelli; A Mazzone; M P Baldacci; A Ferrara; A L Neri; C M Guastoni; R A Bonazzina; B Brando; P Clerici
Journal:  Infection       Date:  2012-02-25       Impact factor: 3.553

Review 3.  Hepatitis D: Scenario in the Asia-Pacific region.

Authors:  Zaigham Abbas; Wasim Jafri; Sajjad Raza
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

4.  Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience.

Authors:  Ibrahim Halil Bahcecioglu; Murat Ispiroglu; Ulvi Demirel; Mehmet Yalniz
Journal:  Hepat Mon       Date:  2015-03-31       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.